Ken Gordon

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

Stephen K. Tyring, Alice B. Gottlieb, Kim Papp et al. · The Lancet · 2005 · 1.1K citations

Psychiatry, Medicine, Clinical Trials +7

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

Alexa B. Kimball, Ken Gordon, S. Fakharzadeh et al. · British Journal of Dermatology · 2012 · 131 citations

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3

Kim Papp, Ken Gordon, Richard G. Langley et al. · British Journal of Dermatology · 2018 · 64 citations

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

Bruce Strober, Alan Menter, C. Leonardi et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 57 citations · Full text

A focus on purpose: using a genre approach in an EFL writing class

Gordon Myskow, Ken Gordon · ELT Journal · 2009 · 55 citations

Second Language Writing, Static Textual Patterns, Writing Assessment +16